Cardiovascular disease remains highly prevalent in the United States and remains the
number one cause of death. 1 Widely disseminated evidence-based clinical practice …

Guidelines from the American College of Cardiology/American Heart Association
(ACC/AHA) and the UK National Institute for Health and Care Excellence (NICE) indicate …

Pharmacologic treatment of hyperlipidemia in conjunction with therapeutic lifestyle changes
can be used for both primary and secondary prevention of cardiovascular disease. Statins …

Hyperlipidemia is a prevalent condition in the United States and a significant contributor to
atherosclerotic cardiovascular disease (ASCVD). ASCVD is a primary cause of morbidity …

Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) are considered to be
the cornerstone of dyslipidemia management and cardiovascular (CV) risk reduction, as …

Atherosclerotic cardiovascular disease (ASCVD) continues to pose a significant global
health challenge, contributing to high rates of morbidity and mortality. Extensive research …

Background Guidelines for managing patients with atherosclerotic cardiovascular disease
(ASCVD) recommend statin therapy initially. Target levels/goals for low-density lipoprotein …

Multiple lines of evidence suggest that the physiologically normal levels of low-density
lipoprotein cholesterol (LDL-C) and the thresholds for development of atherosclerosis and …

Several observations have shown that elevated levels of low-density lipoprotein cholesterol
(LDL-C) are a cause of cardiovascular disease. Lowering LDL-C is a key strategy for …

Discussion The Expert Consensus Decision Pathway document provides specific guidance
on lifestyle interventions, monitoring response of LDL-C to therapy, and statin intolerance, as …